The analysis tool facilitating the detection and treatment of heart disease

“The cardiologist will assess their patient, provide images to Apricot – which is cloud-bound – and our algorithms will take over, perform the analysis and send the report back to the medical team within a few hours while the patient is still in the hospital,” he said.

“The detailed information provided in the report will allow the medical team to make quick decisions about the patient’s health, which may prevent future heart attacks.

“Our goal is to be able to do this in real time in the [catheterisation] laboratory so that the information can also be used to guide the procedure.

Lachlan Kelsey, a UWA adjunct researcher and mechanical engineer, developed Apricot’s algorithms and programmed the software for his PhD.

He said to create that Apricot incorporates machine learning techniques and will continue to evolve with the inclusion of increasing amounts of data as the software is used.

He expects the software to progress as large clinical trials get underway and continue to evolve once the technology begins to be used in real-world settings.

Apricot’s ability to quickly analyze information and present it to medical personnel is the result of years of work to refine the software’s calculation methods.

Kelsey said it’s so cardiologists can access the same information through their laptops within hours instead of relying on the two days of simulation time on a supercomputer.

Doyle said the team — which also includes UWA cardiology professor Carl Schultz — developed Apricot to respond to alarming coronary heart disease statistics.

“In Western Australia, of every patient who has a heart attack and is treated, one in three will either come back with another heart attack or die within three years, despite all the best medical interventions,” Doyle said.

“So Apricot will help people who need immediate treatment, but also to determine what their potential future might look like.”

Detailed images produced by Navier Medical software.

Adapted to the objective

Schultz said to create that Apricot will allow interventional cardiologists to better predict which patients will experience problems so they can offer a more personalized approach in the future.

“It’s important to target particular treatments where they’re needed most. So if we can quickly identify the patients most at risk, they’re the ones who will benefit the most from expensive preventative therapy,” he said. he declares.

Being able to apply Apricot in hospitals around the world took another step forward recently when the team created Navier Medical, a commercial company that has Apricot and a second software called Mosaic as its core products.

Among the attention Apricot has already garnered is recognition of the 2021 Innovator of the Year awards in Western Australia, which was announced as the winner of the Emerging Innovator category in November 2021.

Comments are closed.